What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Myocardial infarction
- Surgery
His primary scientific interests are in Internal medicine, Cardiology, Myocardial infarction, Percutaneous coronary intervention and Surgery.
His Internal medicine study typically links adjacent topics like Anesthesia.
His Cardiology study combines topics in areas such as Percutaneous and Discontinuation.
His Percutaneous coronary intervention study incorporates themes from Continuous variable, Randomized controlled trial, Conventional PCI and Angioplasty.
His Surgery research is multidisciplinary, incorporating elements of Registry data, Clinical trial, Unstable angina and Risk factor.
His studies deal with areas such as Cochrane Library, Regimen, Medical education, Intensive care medicine and Revascularization as well as Clinical trial.
His most cited work include:
- Clinical End Points in Coronary Stent Trials A Case for Standardized Definitions (4102 citations)
- Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. (2883 citations)
- Standardized Bleeding Definitions for Cardiovascular Clinical Trials A Consensus Report From the Bleeding Academic Research Consortium (2146 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Internal medicine, Cardiology, Myocardial infarction, Percutaneous coronary intervention and Conventional PCI.
Internal medicine is frequently linked to Surgery in his study.
His Surgery research incorporates themes from Odds ratio, Clinical trial and Revascularization.
His biological study spans a wide range of topics, including Coronary artery disease and Artery.
His research integrates issues of Platelet aggregation inhibitor, Stent, Discontinuation and Acute coronary syndrome in his study of Percutaneous coronary intervention.
The various areas that Mitchell W. Krucoff examines in his Conventional PCI study include Angina and Emergency medicine.
He most often published in these fields:
- Internal medicine (61.92%)
- Cardiology (53.45%)
- Myocardial infarction (40.09%)
What were the highlights of his more recent work (between 2017-2021)?
- Percutaneous coronary intervention (33.63%)
- Internal medicine (61.92%)
- Conventional PCI (23.83%)
In recent papers he was focusing on the following fields of study:
Mitchell W. Krucoff spends much of his time researching Percutaneous coronary intervention, Internal medicine, Conventional PCI, Cardiology and Myocardial infarction.
His Percutaneous coronary intervention study which covers Percutaneous that intersects with Clinical trial.
His Conventional PCI research includes elements of Anesthesia, Coronary artery disease, Emergency medicine, Clinical endpoint and Non adherence.
Mitchell W. Krucoff usually deals with Emergency medicine and limits it to topics linked to Veterans health and Stent.
His Cardiology study focuses mostly on Acute coronary syndrome, P2Y12 and Ejection fraction.
His Myocardial infarction study frequently links to related topics such as Electrocardiography.
Between 2017 and 2021, his most popular works were:
- Ticagrelor with or without Aspirin in High-Risk Patients after PCI (255 citations)
- Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention : A Consensus Document From the Academic Research Consortium for High Bleeding Risk (189 citations)
- Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention : A Consensus Document From the Academic Research Consortium for High Bleeding Risk (189 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Myocardial infarction
- Surgery
Mitchell W. Krucoff mainly focuses on Percutaneous coronary intervention, Internal medicine, Conventional PCI, Cardiology and In patient.
His studies in Percutaneous coronary intervention integrate themes in fields like Stent, Percutaneous and Surgery.
The study incorporates disciplines such as Clinical endpoint, Pharmacotherapy and Prospective cohort study in addition to Conventional PCI.
His study brings together the fields of Aspirin and Cardiology.
His biological study deals with issues like Clinical trial, which deal with fields such as Health information technology and Medical emergency.
He works on Myocardial infarction which deals in particular with ST segment.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
